Zelira Therapeutics Limited
ZLDAF
$0.2992
$0.041616.15%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -85.63% | -77.14% | -69.37% | -70.43% | -70.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -85.63% | -77.14% | -69.37% | -70.43% | -70.59% |
| Cost of Revenue | -43.48% | -46.62% | -48.98% | -50.12% | -50.69% |
| Gross Profit | -108.65% | 2.24% | 30.21% | -186.87% | -134.44% |
| SG&A Expenses | -84.82% | -66.23% | -52.41% | -61.74% | -65.83% |
| Depreciation & Amortization | -32.43% | -22.64% | -14.47% | -13.96% | -12.84% |
| Other Operating Expenses | 465.52% | -34.04% | -92.21% | -90.94% | -90.05% |
| Total Operating Expenses | -27.77% | -23.73% | -21.74% | -46.97% | -60.12% |
| Operating Income | 24.78% | 21.24% | 19.73% | 45.54% | 59.38% |
| Income Before Tax | 86.63% | 4.19% | -469.32% | -316.85% | -228.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.63% | 4.19% | -469.32% | -316.85% | -228.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -88.67% | -81.20% | -76.19% | -46.13% | -4.61% |
| Net Income | 86.60% | 1.97% | -537.46% | -344.48% | -240.52% |
| EBIT | 24.78% | 21.24% | 19.73% | 45.54% | 59.38% |
| EBITDA | 23.40% | 21.19% | 20.70% | 47.13% | 60.95% |
| EPS Basic | 86.67% | 4.15% | -459.59% | -272.80% | -179.22% |
| Normalized Basic EPS | -24.84% | -6.94% | 6.56% | 53.43% | 73.30% |
| EPS Diluted | 86.67% | 4.15% | -459.59% | -272.80% | -179.22% |
| Normalized Diluted EPS | -24.84% | -6.94% | 6.56% | 53.43% | 73.30% |
| Average Basic Shares Outstanding | 3.60% | 7.96% | 12.70% | 14.85% | 17.16% |
| Average Diluted Shares Outstanding | 3.60% | 7.96% | 12.70% | 14.85% | 17.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |